


The TORPEDO Study Monthly feedback report Site 2303

Date of randomisation 10/10/2011


Date of most recent data extraction 1/11/2012

Screening of cardiovascular risk factors

Performance at Randomisation



Monthly performance trend




Comment:

To meet this indicator all people in the screening population should have smoking status recorded at least once, BP recorded in the last 12 months, and total and HDL cholesterol recorded in the last 24 months.


Your performance: Site 2303 at randomisation was screening at 50% for CVD risk factors, and since then, your performance has improved by 25%.

Chronic kidney disease (CKD) risk factor screening

Performance at Randomisation



Monthly performance trend



Comment:

To meet this indicator all people at risk of CKD should have an eGFR recorded in the last 24 months AND albuminuria assessment in the last 24 months. At risk of CKD is any of the following: Aboriginal people aged ≥30 years. All others with at any of the following: CVD, CKD, Diabetes, current smoker, BMI≥30, current BP medication).


Your performance: At randomization, less than 30% of people at risk of CKD were adequately screened. Since randomisation, this indicator has improved by 10%, exceeding the General Practice average.

The recently released guidelines from Kidney Health Australia now recommend a spot urinary albumin to creatinine ratio test preferably on a first void specimen as the test of choice for albuminuria assessment.

For more information: <http://www.kidney.org.au/HealthProfessionals/CKDManagementinGeneralPractice/tabid/789/Default.aspx>

Prescribing of medicines for individuals at high risk

Performance at Randomisation



Summary

Overall Site 2303 has improved significantly since randomisation in most of the TORPEDO indicators and performing above average on all but one indicator.

Areas identified for improvement at your practice include:

- Prescribing of medicines to people with a CVD diagnosis and risk of CVD.

TORPEDO team would like to arrange the following:

- Our Project Officer to assist your Medical Centre staff.
- We are happy to assist in any way.

We would welcome any feedback you may have on this feedback report and look forward to working with you as the study progresses.

Dr David Peiris
Chief Investigator TORPEDO Study
The George Institute for Global Health
dpeiris@georgeinstitute.org.au

Maria Agaliotis
Project Officer TORPEDO Study
The George Institute for Global Health
magaliotis@georgeinstitute.org.au
02 9993 4524